A comprehensive analysis of development attrition in drug candidates from four major pharmaceutical companies
Owen B. Wallace(Eli Lilly (United States)), Alex. M. Weir(Thomson Reuters (United Kingdom)), Paul D. Leeson(RED Consulting (Norway)), Ji‐Bo Wang(Kunming University of Science and Technology), Robert M. Owen(Pfizer (United States)), Michael J. Waring(Newcastle University), Stephen D. Pickett(Ligand Pharmaceuticals (United Kingdom)), Garry Pairaudeau(AstraZeneca (United Kingdom)), John Arrowsmith(Thomson Reuters (United Kingdom)), Sam Mandrell(Thomson Reuters (United Kingdom)), William D. Pennie(Pfizer (United States)), Andrew R. Leach(LifeArc)
Unknown
January 1, 2015
Cited by 2
Related Papers
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
|Journal of Molecular Biology|1997|6.7k
ChEMBL: towards direct deposition of bioassay data
|Nucleic Acids Research|2018|2.5k
The ChEMBL database in 2017
|Nucleic Acids Research|2016|2.4k
Molecular Modelling: Principles and Applications
|Unknown|1996|1.9k
An analysis of the attrition of drug candidates from four major pharmaceutical companies
|Nature Reviews Drug Discovery|2015|1.4k